Risankizumab is a humanized monoclonal antibody that targets interleukin (IL-)23, approved for the treatment of moderate-to-severe plaque psoriasis, which has shown efficacy in both clinical trials and real-world experiences.1–4 However, there is still limited knowledge regarding which patients could benefit the most from the therapy with risankizumab

A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Damiani G;Girolomoni G;Lasagni C;Maurelli M;Orsini D;
2024-01-01

Abstract

Risankizumab is a humanized monoclonal antibody that targets interleukin (IL-)23, approved for the treatment of moderate-to-severe plaque psoriasis, which has shown efficacy in both clinical trials and real-world experiences.1–4 However, there is still limited knowledge regarding which patients could benefit the most from the therapy with risankizumab
2024
risankizumab super responder profile identified by long-term real-life observation-IL PSO
File in questo prodotto:
File Dimensione Formato  
Gargiulo RIS JEADV 2024.pdf

accesso aperto

Licenza: Dominio pubblico
Dimensione 2.01 MB
Formato Adobe PDF
2.01 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1116595
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 2
social impact